Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Wojciech Świerczyński"'
Autor:
Tomasz Aleksiewicz, Kamil Leis, Wojciech Świerczyński, Kacper Miętkiewicz, Katarzyna Litwin, Przemysław Gałązka
Publikováno v:
Journal of Education, Health and Sport, Vol 8, Iss 9, Pp 424-437 (2018)
Mirabegron has been registered as the first strong and selective agonist of the β3 receptor. It is currently used for relief of symptoms of overactive bladder (OAB). That onerous illness involving urgency and detrusor overactivity, that may be accom
Externí odkaz:
https://doaj.org/article/45846451e09c429099748cb9480dbd92
Autor:
Przemysław Gałązka, Kamil Leis, Wojciech Świerczyński, Mariusz Racinowski, Ewelina Mazur, Aleksandra Baska
Publikováno v:
Endocrine, metabolicimmune disorders drug targets. 20(9)
Mirabegron is a β3-agonist drug approved by the FDA for use in 2012 and administered in overactive bladder. Activating of adrenergic receptors leads to the relaxation of the detrusor muscle. According to the latest research and reports, it also has
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75c854a61335026f018bcd79f7418d07
https://pubmed.ncbi.nlm.nih.gov/32416711
https://pubmed.ncbi.nlm.nih.gov/32416711